[Risk assessment of medication-related osteonecrosis of the jaw in general dental practice].

Orv Hetil

Konzerváló Fogászati Klinika, Semmelweis Egyetem, Fogorvostudományi Kar Budapest, Üllői út 26., 1085.

Published: February 2019

Medication-related osteonecrosis of the jaw may appear as adverse effect in antiresorptive therapy. Its successful treatment is challenging. We aimed to gather the systemic and local factors playing a role in etiology, published after its recognition. Risk factors were collected from the PubMed database 1998-2018. The three main groups of risk patients are: patients starting, patients having antiresorptive therapy, osteonecrosis diagnosed patients. The dentist must recognize risk factors, determine appropriate treatment plan and frequency of check-ups. Oncological disease treated intravenously means the greatest risk. Further systemic risk factors are: supportive therapies, concomitant disease, way of life, individual factors. Local risk factors may be: dentoalveolar surgery, periapical and periodontal inflammation, ill-fitting denture, presence of some anatomical structures. The accumulation of risk factors determines the probability of the manifestation of osteonecrosis. The most favorable case is patient starting antiresorptive therapy with a dental status needing no treatment. Orv hetil. 2019; 160(7): 243-251.

Download full-text PDF

Source
http://dx.doi.org/10.1556/650.2019.31204DOI Listing

Publication Analysis

Top Keywords

risk factors
20
antiresorptive therapy
12
medication-related osteonecrosis
8
osteonecrosis jaw
8
factors
7
risk
7
[risk assessment
4
assessment medication-related
4
osteonecrosis
4
jaw general
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!